Latest News

30 October 2014

Starpharma raises $3.5M through SPP following $18M Placement

Starpharma today announced it has raised a total of approximately $21.5 million following the closing of its Share Purchase Plan (SPP) on Wednesday 29 October 2014. The Company raised approximately $3.5 million from existing eligible shareholders through the SPP. The SPP followed the Company’s recent $18 million share placement to sophisticated and institutional investors, which was significantly oversubscribed. 

Read more

29 October 2014

Starpharma receives $4.2 million R&D tax incentive refund

Starpharma today announced it has received the anticipated $4.2M of R&D tax incentive refund relating to FY14 expenditures.  

Read more

29 October 2014

VivaGel® condom now available in Australian stores

Starpharma is pleased to announce that the Company has been notified by its commercial partner, Ansell (ASX:ANN), that the VivaGel® condom is now available for purchase from Woolworths stores in Australia under Ansell’s brand, LifeStyles® Dual Protect™. 

Read more

21 October 2014

Starpharma Boardroom Radio Interview

Starpharma is pleased to provide investors with the opportunity to listen to an audio interview with Chief Executive Officer Dr Jackie Fairley on Boardroom Radio (BRR).

Read more

In the media

7 August 2014

The Business on ABC TV: Interview with Starpharma CEO Jackie Fairley

Starpharma CEO Jackie Fairley joins The Business’ Presenter Ticky Fullerton to discuss TGA approval of a VivaGel coated condom in depth, revisiting the shorting issue covered prior on the show, the benefits of the announcement to broader Australian innovation, and a business update on Starpharma’s DEP docetaxel drug development. 

Read more

7 August 2014

Glamour UK: Potential Huge News: This New Condom May Be Able to Kill HIV, Herpes, and Other STDs

Glamour UK, a magazine for women with a UK online readership of 3.38 million, covered the announcement that Starpharma had received TGA approval for VivaGel coated condoms. 

Read more

7 August 2014

The Washington Times: HIV-killing condom to soon hit shelves in Australia

The Washington Times’ picked up the announcement that Starpharma and Ansell have received TGA approval of the VivaGel coated condom from The Daily Mail UK.  

Read more

7 August 2014

The Daily Mail: First condom designed to kill HIV "could be available to buy within months"

In an article that goes into a significant amount of scientific detail for a mainstream news publication, the Daily Mail covered the TGA of VivaGel coated condoms announcement. 

Read more

Shareholder Updates

7 October 2014

Shareholder Update October 2014

In this Issue:

› Encouraging clinical data for DEP™ docetaxel

› VivaGel® condom approved for sale in Australia – Launch imminent

› VivaGel® for BV: SPA agreement for Phase 3 and commercialisation activities for Symptomatic Relief

› Starpharma completes $18M Placement; launches $5M SPP

› Dendrimer-enhanced agrochemicals

› Full Year 2014 annual financial results


Download: Shareholder Update October 2014 (pdf file, 1MB)

12 June 2014

Shareholder Update: June 2014

In this issue:

› VivaGel® BV prevention of recurrence: start of phase 3 trials close

› R&D tax incentive cash received

› DEP™ docetaxel trial progressing well

› VivaGel®-coated condom: preparing for launch

› VivaGel® BV symptomatic relief product: commercial and regulatory progress

› Strong results for dendrimer enhanced agrochemicals


Download: Shareholder Update: June 2014 ( pdf file, 2MB)

Sign up to receive news here

© Starpharma Holdings Limited 2014